报价延迟最少15分钟:2026/04/15 16:27 EDT
盘后时段
|
||||
|
4.87 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.87
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.18/-1.02
|
|
企业价值
325.04M
|
| 资产负债 |
|
每股账面净值
-1.85
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
30.91M
|
|
每股收益
0.55
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909. |
